394 related articles for article (PubMed ID: 22262587)
1. The US Food and Drug Administration's Sentinel Initiative: expanding the horizons of medical product safety.
Robb MA; Racoosin JA; Sherman RE; Gross TP; Ball R; Reichman ME; Midthun K; Woodcock J
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():9-11. PubMed ID: 22262587
[No Abstract] [Full Text] [Related]
2. The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction.
Platt R; Carnahan RM; Brown JS; Chrischilles E; Curtis LH; Hennessy S; Nelson JC; Racoosin JA; Robb M; Schneeweiss S; Toh S; Weiner MG
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():1-8. PubMed ID: 22262586
[TBL] [Abstract][Full Text] [Related]
3. Design considerations, architecture, and use of the Mini-Sentinel distributed data system.
Curtis LH; Weiner MG; Boudreau DM; Cooper WO; Daniel GW; Nair VP; Raebel MA; Beaulieu NU; Rosofsky R; Woodworth TS; Brown JS
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():23-31. PubMed ID: 22262590
[TBL] [Abstract][Full Text] [Related]
4. Using high-dimensional propensity scores to automate confounding control in a distributed medical product safety surveillance system.
Rassen JA; Schneeweiss S
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():41-9. PubMed ID: 22262592
[TBL] [Abstract][Full Text] [Related]
5. A policy framework for public health uses of electronic health data.
McGraw D; Rosati K; Evans B
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():18-22. PubMed ID: 22262589
[TBL] [Abstract][Full Text] [Related]
6. Safety in numbers--monitoring risk in approved drugs.
Okie S
N Engl J Med; 2005 Mar; 352(12):1173-6. PubMed ID: 15788493
[No Abstract] [Full Text] [Related]
7. FDA attempting to overcome major roadblocks in monitoring drug safety.
Zielinski SL
J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
[No Abstract] [Full Text] [Related]
8. The Food and Drug Administration's Post-Licensure Rapid Immunization Safety Monitoring program: strengthening the federal vaccine safety enterprise.
Nguyen M; Ball R; Midthun K; Lieu TA
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():291-7. PubMed ID: 22262619
[TBL] [Abstract][Full Text] [Related]
9. Form for reporting serious adverse events and product problems with human drug and biological products and devices; availability--FDA. Notice.
Fed Regist; 1993 Jun; 58(105):31596-614. PubMed ID: 10171452
[TBL] [Abstract][Full Text] [Related]
10. The FDA's sentinel initiative--A comprehensive approach to medical product surveillance.
Ball R; Robb M; Anderson SA; Dal Pan G
Clin Pharmacol Ther; 2016 Mar; 99(3):265-8. PubMed ID: 26667601
[TBL] [Abstract][Full Text] [Related]
11. MedWatch: the new medical products reporting program.
Couig MP; Merkatz RB
Am J Nurs; 1993 Aug; 93(8):65-8. PubMed ID: 8256839
[No Abstract] [Full Text] [Related]
12. The MedWatch Program.
Love L; Couig MP
J Toxicol Clin Toxicol; 1999; 37(6):803-7. PubMed ID: 10584596
[No Abstract] [Full Text] [Related]
13. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems.
Glasser SP; Salas M; Delzell E
J Clin Pharmacol; 2007 Sep; 47(9):1074-86. PubMed ID: 17766697
[TBL] [Abstract][Full Text] [Related]
14. FDA works to reduce preventable medical device injuries.
Rados C
FDA Consum; 2003; 37(4):29-33. PubMed ID: 12971346
[No Abstract] [Full Text] [Related]
15. Statistical approaches to group sequential monitoring of postmarket safety surveillance data: current state of the art for use in the Mini-Sentinel pilot.
Cook AJ; Tiwari RC; Wellman RD; Heckbert SR; Li L; Heagerty P; Marsh T; Nelson JC
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():72-81. PubMed ID: 22262595
[TBL] [Abstract][Full Text] [Related]
16. Mini-Sentinel's systematic reviews of validated methods for identifying health outcomes using administrative and claims data: methods and lessons learned.
Carnahan RM; Moores KG
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():82-9. PubMed ID: 22262596
[TBL] [Abstract][Full Text] [Related]
17. MedWatch. On lookout for medical product problems.
Ropp KL
FDA Consum; 1993 Nov; 27(9):14-7. PubMed ID: 10130376
[No Abstract] [Full Text] [Related]
18. Toward improved adverse event/suspected adverse drug reaction reporting.
Gross R; Strom BL
Pharmacoepidemiol Drug Saf; 2003 Mar; 12(2):89-91. PubMed ID: 12642971
[No Abstract] [Full Text] [Related]
19. Computerized medical device tracking--ways to comply with SMDA (Safe Medical Devices Act of 1990).
Landis D
Healthc Inform; 1992 Jul; 9(7):36, 38, 40-2. PubMed ID: 10119858
[No Abstract] [Full Text] [Related]
20. The Food and Drug Administration's Drug Safety Oversight Board: an evolving paradigm for clinical input on drug safety topics.
Grandinetti CA; Osborne SF
Clin Pharmacol Ther; 2010 Aug; 88(2):269-74. PubMed ID: 20531466
[No Abstract] [Full Text] [Related]
[Next] [New Search]
